Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Spondyloarthritis Patients

NCT ID: NCT02869100

Last Updated: 2016-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to compare detection of axial inflammatory lesions in patients affected by spondyloarthritis (SpA) with sodium fluoride positron emission tomography (PET) and magnetic resonance imaging (MRI), the reference technique.

It would be interesting to show the superiority of sodium fluoride PET on MRI for diagnosis of inflammatory lesions. It could be used for diagnostic care but also therapeutic care of patients with early forms of spondyloarthritis.

Secondary purposes are:

* To evaluate performances of sodium fluoride PET in detection of SpA peripheral damage (except spine and sacroiliac joints)
* To evaluate bone inflammation (axial and peripheral) with sodium fluoride PET and compare these data to clinic-biologic parameters used in clinical practice (BASDAI, BASFI, BASMI, sedimentation rate, C-reactive protein (CRP)) and to structural evaluation (sacroiliac New York, mSASSS and BASRI scoring methods)
* To study correlation of axial and peripheral bone inflammation (spine and sacroiliac joints) evaluated with sodium fluoride PET with biologic markers of inflammation and bone remodeling (MMP-3; DKK-1, IL-6, IL-17, TNF-α).

Known biologic markers of inflammation in SpA are correlated to activity obtained with MRI. It is interesting to compare to activity obtained with PET. Moreover, it has been recently showed the disassociation of inflammation and structural progression (anti-TNF treatments do not prevent structural progression) that is associated to markers of bone remodeling whose activity is influenced by an activation/inhibition system of biologic markers of inflammation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondyloarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spondyloarthritis Patients

Group Type EXPERIMENTAL

Blood sample

Intervention Type OTHER

Sodium fluoride Positron Emission Tomography

Intervention Type PROCEDURE

Magnetic Resonance Imaging

Intervention Type OTHER

Radiography

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Intervention Type OTHER

Sodium fluoride Positron Emission Tomography

Intervention Type PROCEDURE

Magnetic Resonance Imaging

Intervention Type OTHER

Radiography

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-50 year-old patients affected by axial or mixed SpA (ASAS criteria) or \>18 year-old patients according to New York criteria
* Patients with bone marrow edema lesions in sacroiliac joints and/or spine detected with MRI
* No therapeutic changes between hospitalization for evaluation of SpA activity and inclusion visit
* Informed consent
* Affiliation to social security plan

Exclusion Criteria

* Refusal or impossibility of signed informed consent
* Doubt about possible pregnancy in women of childbearing potential
* Pregnancy and breastfeeding
* History of drug addiction, alcoholism, psychological problems, severe co-morbidities
* Renal insufficiency (creatinine clearance \< 60 ml/min)
* Juridical protection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre OLIVIER, Pr

Role: PRINCIPAL_INVESTIGATOR

CHU de Nancy, Hôpitaux de Brabois, service de Médecine Nucléaire

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Nancy, Hôpitaux de Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-A00568-35

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Characterizing Myositis With 68Ga-FAPI PET/CT
NCT05952531 UNKNOWN EARLY_PHASE1
Chronic Fatigue in Sarcoidosis
NCT04178239 COMPLETED
MRI for Screening and Monitoring Scleroderma ILD
NCT05204355 ACTIVE_NOT_RECRUITING